ENDEAVOR DES System Gets Thumbs Up from FDA
The FDA Advisory Committe recommends approval of a new type of stent system – the Medtronic ENDEAVOR zotarolimus-eluting coronary stent system [1].
Data from the latest clinical trials which included over 4100 patients affirm the efficacy and safety of ENDEAVOR.
ENDEAVOR Efficacy in terms of target vessel failure (TVF) and target lesion vascularization (TLV) is shown to be comparable to that of TAXUS. ENDEAVOR safety profile is shown to be better than that of TAXUS and CYPHER [2].
After the recent safety concerns about DES, ENDEAVOR might just save the day.
No Comments
Be the first to comment!